Polomar Health Services Strengthens Board Leadership to Support Standalone Growth Strategy

Polomar Health Services, Inc., a medical care services organization working on a specialty compounding pharmacy and prescription-fulfillment platform, announced changes to its Board of Directors as the Company advances its growth approches.

Effective, George Hornig has been appointed Executive Chairman of the Board of Directors. George Caruolo has joined the Board and serves as Lead Independent Director. Furthermore, Gabrielle Toledano and Alexandra Peterson have joined the Board, while Gabriel Del Virginia will continue to serve as a member.

The supported Board leadership brings more experience in public-based company governance, capital markets, working approaches, medical care, and government matters. Polomar is reviewing its commercial urgencies, product mix, and functioning roadmap, and expects to offer a wider business update after the completion of that review.

“I look forward to working with the new members of our expanded Board in implementing our strategic initiatives and vision for continued growth, focusing on products that promote overall health, wellness, and longevity,” said Terrence M. Tierney, Interim Chief Executive Officer of Polomar.

“Polomar is entering an important new chapter, and I am pleased to join the Company as Executive Chairman,” said George Hornig. “The Board will work closely with management to build on Polomar’s existing healthcare services platform, refine its commercial priorities, and pursue the opportunities that offer the greatest potential for long-term value creation. Our focus will be on disciplined execution, strong governance, and positioning the Company for sustainable growth.”

Trak Ground Wear situates itself in a new division, the brand calls “ground wear,” gear designed to supports the body’s foundation. TRAK Compression is obtainable at trakgroundwear.com starting May, priced at $45.

George Hornig, Executive Chairman, has extensive experience serving on the boards of public and private organizations. He is Managing Partner and Co-Founder of The Seed Lab and previously served as Chairman of Xometry, Co-Chairman and Audit Chair of Healthwell Acquisition Corp., and a director of Syntax Advisors. His earlier career involved senior leadership roles at PineBridge Investments, Credit Suisse Asset Management, and Deutsche Bank Americas. He holds A.B., J.D., and M.B.A. degrees from Harvard University.

George Caruolo, Lead Independent Director, is an attorney and advisor with wide experience in governance, public service, and regulatory affairs. They earlier served in the Rhode Island House of Representatives, including as Majority Leader. He has served on many boards, commissions, and audit committees, involving the Board of Directors of Lifespan, Inc., and the Rhode Island Board of Regents for Elementary and Secondary Education, where he served in a position.

Gabriel Del Virginia has massive experience such as more than 30 years of advising public and private organizations on corporate matters, acquisitions and mergers, economic, litigation, and economic restructuring. He has served as a director of Polomar and has held leadership roles on the organization’s Board committees.

Gabrielle Toledano has joined the Board, bringing more than 30 years of experience as a working executive, advisor, and border director in the gaming, technology, and digital transformation. She currently assists as Chief Operating Officer of significant approaches and earlier held senior leadership roles at Tesla, Electronic Arts, and Siebel Systems. She presently serves on the boards of IonQ and Fountain.

According to Towards Healthcare, the compounding pharmacy market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 14.58 billion in 2025 to approximately USD 22.91 billion by 2034, representing a compound annual growth rate (CAGR) of 5.15% from 2025 to 2034, driven by compounding pharmacies are significant to contemporary medicalcare because they offers customized services that cater to every patient's specific demands. In pediatric care, allergies or medicine shortages, compounding provides an adaptable and effective substitute for mass-produced healthcare.

Compounding increases therapeutic adherence by providing specific dosages and formulations. When a therapeutic is easy to use, non-irritating, and customized to the patient's preferences, the patient is more likely to take it. It provides better management results and an improved quality of life result from this approach. Pharmaceutical compounding lowers the medication regimen complexity by offering particular drug integration that brings together numerous commercial medicines in one single dosage form.

About Polomar Health Services, Inc.

Polomar Health Services, Inc. operates Polomar Specialty Pharmacy, LLC, a Florida-licensed retail compounding pharmacy located in Palm Harbor, Florida. Polomar Specialty Pharmacy grips sterile and non-sterile compounding permits and offers prescription-fulfillment solutions for compounded therapeutics. The organization significantly focused on increasing its medical care solutions platform and supporting third-party telehealth offers via prescription fulfillment abilities. For more information, visit www.polomarhs.com.

A recent report by Towards Healthcare highlights that the compounding pharmacy market is witnessing growth because compounding pharmacies offer personalized strategies to medical care, providing customized medications intended to meet the specific requirement of each patient. Compounding pharmacies support bridging the gap during medication shortages or discontinuations. By manufacturing equivalent formulations, they confirm patients continue receiving the therapies they require without interruption. This ability is specifically advantageous for rare or niche therapeutics which may no longer be commercially available. Compounding is particularly valuable for children, who often need medications in particular dosages or flavors to make them more edible. A pediatric patient benefits from a flavored liquid version of a therapeutics.